<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765202</url>
  </required_header>
  <id_info>
    <org_study_id>MNK01062117</org_study_id>
    <nct_id>NCT04765202</nct_id>
  </id_info>
  <brief_title>StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns</brief_title>
  <acronym>StrataSOMA</acronym>
  <official_title>A Phase 1/2a, Controlled, Randomized, Multicenter Study Evaluating the Efficacy, Safety, Tolerability of StrataGraft Overlay of Meshed Autograft (SOMA) in Treatment of Full-Thickness Thermal Burns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stratatech, a Mallinckrodt Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autografting is a surgical procedure to transplant healthy skin (donor skin) from another&#xD;
      part of the patient's own body (donor site) to the burned part. Autografting is the usual&#xD;
      treatment for full-thickness (FT) burns.&#xD;
&#xD;
      It works to close the wound, but can cause other problems:&#xD;
&#xD;
        -  Donor sites are painful, can become infected or scarred, or can even become FT wounds&#xD;
           themselves&#xD;
&#xD;
        -  Treatment problems can require more grafting&#xD;
&#xD;
        -  Additional surgery increases risk of medical problems caused by the treatment&#xD;
&#xD;
      Stratatech is trying to find a safe and effective treatment option for severe burns that uses&#xD;
      less donor skin.&#xD;
&#xD;
      All participants in this study will receive meshed autograft on one part of their burn (AG&#xD;
      Tx). They will receive meshed autograft with a StrataGraft covering (SOMA Tx) on a different&#xD;
      part of their burn.&#xD;
&#xD;
      Each participant will be involved in the study up to about 14 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Within-patient controlled - treatment sites on the same patient are randomized to be test or control&#xD;
This means each participant receives both study treatments and serves as their own control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>While the treatment itself is open label, the outcomes assessor will not know the treatment applied to each treatment site until after assessing the outcomes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment sites with complete wound closure without additional autografting at Month 2</measure>
    <time_frame>at Month 2</time_frame>
    <description>Complete wound closure is defined as complete skin re-epithelialization without drainage confirmed at 2 visits at least 2 weeks apart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with durable wound closure of the study treatment sites without additional autografting at Month 12</measure>
    <time_frame>at Month 12</time_frame>
    <description>Durable wound closure is defined as persistence of closure, maintained for at least 3 months after the initial observation of closure.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Full Thickness Burn</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive both treatments.&#xD;
On each participant, similar wounds will be identified as treatment sites.&#xD;
Treatment sites will be randomized to receive either AG Tx (control) or SOMA Tx (experimental).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AG Tx</intervention_name>
    <description>The control treatment is meshed autograft applied to a FT burn area</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>Meshed Autograft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SOMA Tx</intervention_name>
    <description>The experimental treatment is meshed autograft applied to a FT burn area and covered with SOMA</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>StrataGraft skin tissue Overlay of Meshed Autograft (SOMA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has 3% to 49% (inclusive) total body surface area (TBSA) thermal burn area, including&#xD;
             areas of full thickness (FT) injury clinically indicated for surgical excision and&#xD;
             autografting, appropriate for protocol-defined treatment areas&#xD;
&#xD;
          -  Meets protocol-specified criteria for qualification and contraception&#xD;
&#xD;
          -  Is willing and able to comply with all study procedures and requirements&#xD;
&#xD;
          -  Voluntarily consents to participate and provides written informed consent prior to any&#xD;
             protocol-specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is a prisoner, pregnant, or had previous treatment of the burn sites&#xD;
&#xD;
          -  Is expected to survive less than 3 months&#xD;
&#xD;
          -  Is participating in another interventional trial, or did within 30 days before&#xD;
             enrollment&#xD;
&#xD;
          -  Has anticipated treatment sites that are outside protocol-specified parameters&#xD;
&#xD;
          -  Has concurrent clinically significant inhalation injury, inadequate fluid&#xD;
             resuscitation, or burns of chemical or electrical (non-thermal) etiology&#xD;
&#xD;
          -  Has other signs, symptoms or history of any condition that, per protocol or in the&#xD;
             opinion of the investigator, might compromise:&#xD;
&#xD;
               1. the safety or well-being of the participant&#xD;
&#xD;
               2. the study objectives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Team Leader</last_name>
    <role>Study Director</role>
    <affiliation>Stratatech, a Mallinckrodt Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medstar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>202-877-7347</phone>
      <email>jeffrey.w.shupp@medstar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UF Health Burn Center at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>352-273-5670</phone>
      <email>joshua.carson@surgery.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baton Rouge General Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>225-237-1672</phone>
      <email>patricia.pinsonat@brgeneral.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>631-624-7101</phone>
      <email>adam.singer@stonybrookmedicine.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center Burn Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>336-716-4278</phone>
      <email>cgruver@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>843-792-8824</phone>
      <email>hirschj@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carisoprodol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

